Long-Term Outcomes of Primary Trabeculectomy in Diabetic Patients without Retinopathy with Primary Angle-Closure Glaucoma

Table 2

Intraocular pressure, medical therapy, and BCVA at follow-up.

Postoperative follow-ups	DM group	Control group
6 months
Number of eyes	88	97
IOP (mmHg)	12.0 ± 4.6	11.2 ± 4.6	0.239
Glaucoma medications	0.8 ± 0.9	0.6 ± 0.9	0.198
Visual acuity in logMAR	0.29 ± 0.32	0.29 ± 0.33	1.000
1 year
Number of eyes	88	97
IOP (mmHg)	12.9 ± 4.9	11.4 ± 4.5	0.036
Glaucoma medications	1.3 ± 1.3	0.6 ± 0.9	0.000
BCVA (logMAR)	0.33 ± 0.42	0.32 ± 0.45	0.876
2 years
Number of eyes	76	81
IOP (mmHg)	13.3 ± 5.2	11.6 ± 4.9	0.036
Glaucoma medications	1.3 ± 1.3	0.8 ± 1.2	0.013
BCVA (logMAR)	0.36 ± 0.46	0.34 ± 0.49	0.793
3 years
Number of eyes	60	63
IOP (mmHg)	13.5 ± 5.6	11.6 ± 5.0	0.049
Glaucoma medications	1.3 ± 1.4	0.8 ± 1.3	0.042
BCVA (logMAR)	0.42 ± 0.59	0.40 ± 0.61	0.853
4 years
Number of eyes	50	59
IOP (mmHg)	13.9 ± 4.8	12.0 ± 4.9	0.044
Glaucoma medications	1.5 ± 1.5	1.0 ± 1.1	0.047
BCVA (logMAR)	0.47 ± 0.43	0.45 ± 0.43	0.809
5 years
Number of eyes	42	51
IOP (mmHg)	15.0 ± 5.6	12.4 ± 5.3	0.024
Glaucoma medications	1.7 ± 1.5	1.1 ± 1.4	0.049
BCVA (logMAR)	0.51 ± 0.21	0.50 ± 0.15	0.789